A Phase 2 Study of Gemtuzumab Ozogamicin (GO)-Gilteritinib Combination in Adults with FLT3-ITD Relapse/refractory (R/R) AML

PHASE2RecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

June 3, 2023

Primary Completion Date

March 15, 2027

Study Completion Date

March 15, 2027

Conditions
AML
Interventions
COMBINATION_PRODUCT

Gemtuzumab ozogamicine - Cytarabine - Gilteritinib

See Arms description paragraph

Trial Locations (30)

Unknown

RECRUITING

CHU d'Amiens, Amiens

NOT_YET_RECRUITING

CHU d'Angers, Angers

RECRUITING

CH Victor Dupouy, Argenteuil

NOT_YET_RECRUITING

Hôpital Avicenne, Bobigny

RECRUITING

CHU Bordeaux, Bordeaux

RECRUITING

CHU de Caen, Caen

RECRUITING

CHMS de Chambery, Chambéry

RECRUITING

HIA Percy, Clamart

RECRUITING

CHU Henri Mondor, Créteil

RECRUITING

CHU Limoges, Limoges

NOT_YET_RECRUITING

Centre Léon Bérard, Lyon

RECRUITING

Hôpital Lyon sud, Lyon

NOT_YET_RECRUITING

Hôpital la Timone Conception, Marseille

RECRUITING

CH de Meaux, Meaux

RECRUITING

CHRU Nancy, Nancy

RECRUITING

CHU Nantes, Nantes

RECRUITING

Centre Antoine Lacassagne, Nice

RECRUITING

Centre Hospitalier Universitaire de Nice, Nice

RECRUITING

CHR Orléans, Orléans

NOT_YET_RECRUITING

Hôpital de la Pitié Salpétrière, Paris

NOT_YET_RECRUITING

Hôpital Necker, Paris

NOT_YET_RECRUITING

Hôpital Saint Louis, Paris

RECRUITING

CHU Poitiers, Poitiers

RECRUITING

CH René Dubos, Pontoise

NOT_YET_RECRUITING

CHU Robert Debré, Reims

RECRUITING

CHU Pontchaillou, Rennes

RECRUITING

Centre Henri Becquerel, Rouen

RECRUITING

CHRU Bretonneau, Tours

RECRUITING

Centre Hospitalier de Versailles, Versailles

NOT_YET_RECRUITING

IGR, Villejuif

Sponsors

Collaborators (2)

All Listed Sponsors
collaborator

Acute Leukemia French Association

OTHER

collaborator

Astellas Pharma Inc

INDUSTRY

collaborator

Pfizer

INDUSTRY

lead

Centre Antoine Lacassagne

OTHER